UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 27.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 381,508 shares of the biotechnology company's stock after selling 145,240 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.71% of Prothena worth $5,284,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Virtus ETF Advisers LLC boosted its position in shares of Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after buying an additional 833 shares during the last quarter. Headlands Technologies LLC lifted its stake in Prothena by 196.5% during the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 4,858 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of Prothena in the fourth quarter worth approximately $145,000. Purkiss Capital Advisors LLC purchased a new position in shares of Prothena during the fourth quarter valued at approximately $149,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,065 shares during the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities research analysts recently issued reports on PRTA shares. Oppenheimer cut shares of Prothena from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 27th. Royal Bank of Canada dropped their price target on Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Friday, February 21st. Chardan Capital reduced their price objective on Prothena from $40.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, May 27th. HC Wainwright lowered their target price on Prothena from $30.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 27th. Finally, JMP Securities dropped their target price on Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Prothena presently has a consensus rating of "Hold" and a consensus price target of $31.50.
Read Our Latest Research Report on Prothena
Prothena Stock Up 1.0%
PRTA traded up $0.05 during midday trading on Wednesday, reaching $4.88. The company had a trading volume of 1,140,960 shares, compared to its average volume of 696,541. The business has a 50-day moving average of $8.54 and a two-hundred day moving average of $12.31. Prothena Co. plc has a 1 year low of $4.32 and a 1 year high of $25.42. The company has a market cap of $262.68 million, a P/E ratio of -2.12 and a beta of 0.11.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $8.18 million. During the same quarter last year, the firm posted ($1.34) earnings per share. The company's revenue was up 5500.0% compared to the same quarter last year. On average, equities research analysts predict that Prothena Co. plc will post -4.04 EPS for the current year.
Prothena Company Profile
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
